Home Cart 0 Sign in  

[ CAS No. 686-50-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 686-50-0
Chemical Structure| 686-50-0
Structure of 686-50-0 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 686-50-0 ]

Related Doc. of [ 686-50-0 ]

Alternatived Products of [ 686-50-0 ]

Product Details of [ 686-50-0 ]

CAS No. :686-50-0 MDL No. :MFCD00065940
Formula : C8H16N2O3 Boiling Point : -
Linear Structure Formula :- InChI Key :LESXFEZIFXFIQR-LURJTMIESA-N
M.W : 188.22 Pubchem ID :97364
Synonyms :
H-Leu-Gly-OH

Calculated chemistry of [ 686-50-0 ]

Physicochemical Properties

Num. heavy atoms : 13
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.75
Num. rotatable bonds : 6
Num. H-bond acceptors : 4.0
Num. H-bond donors : 3.0
Molar Refractivity : 48.05
TPSA : 92.42 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -9.1 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.21
Log Po/w (XLOGP3) : -2.33
Log Po/w (WLOGP) : -0.44
Log Po/w (MLOGP) : -0.3
Log Po/w (SILICOS-IT) : -0.4
Consensus Log Po/w : -0.45

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 2.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : 0.86
Solubility : 1350.0 mg/ml ; 7.19 mol/l
Class : Highly soluble
Log S (Ali) : 0.93
Solubility : 1590.0 mg/ml ; 8.43 mol/l
Class : Highly soluble
Log S (SILICOS-IT) : -0.58
Solubility : 49.6 mg/ml ; 0.264 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.95

Safety of [ 686-50-0 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 686-50-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 686-50-0 ]

[ 686-50-0 ] Synthesis Path-Downstream   1~72

  • 1
  • [ 57-48-7 ]
  • [ 686-50-0 ]
  • <i>N</i>-(<i>N</i>-D-glucose-2-yl-L-leucyl)-glycine [ No CAS ]
  • 2
  • [ 7154-27-0 ]
  • [ 686-50-0 ]
  • 6
  • [ 686-50-0 ]
  • [ 66-72-8 ]
  • (4-methyl-2-oxo-pentanoylamino)-acetic acid [ No CAS ]
  • 7
  • [ 686-50-0 ]
  • [ 70-34-8 ]
  • [ 92325-87-6 ]
  • 9
  • [ 64-17-5 ]
  • [ 686-50-0 ]
  • [ 53375-57-8 ]
  • 10
  • [ 686-50-0 ]
  • [ 37734-45-5 ]
  • N-Benzylthiocarbonyl-L-leucylglycin [ No CAS ]
  • 11
  • [ 686-50-0 ]
  • [ 19912-32-4 ]
  • Leucyl-glycinanhydrid [ No CAS ]
  • 13
  • [ 686-50-0 ]
  • [ 79-04-9 ]
  • [ 2576-68-3 ]
  • 15
  • [ 686-50-0 ]
  • [ 840-97-1 ]
  • Ac-Tyr-Leu-Gly [ No CAS ]
  • 16
  • [ 686-50-0 ]
  • [ 5672-83-3 ]
  • [ 135875-27-3 ]
  • 17
  • [ 686-50-0 ]
  • [ 80556-22-5 ]
  • C17H26N3O7P [ No CAS ]
  • 18
  • [ 686-50-0 ]
  • [ 88576-96-9 ]
  • [ 95753-58-5 ]
  • 19
  • [ 686-50-0 ]
  • [ 88576-96-9 ]
  • [ 95753-59-6 ]
  • 20
  • [ 686-50-0 ]
  • [ 57358-86-8 ]
  • [ 57212-41-6 ]
  • 22
  • [ 56-40-6 ]
  • [ 3190-70-3 ]
  • [ 686-50-0 ]
  • [ 462-60-2 ]
  • 23
  • [ 686-50-0 ]
  • [ 98-88-4 ]
  • [ 118-92-3 ]
  • (S)-4-Methyl-2-[2-(4-oxo-2-phenyl-4H-quinazolin-3-yl)-acetylamino]-pentanoic acid [ No CAS ]
  • 24
  • [ 686-50-0 ]
  • [ 98-88-4 ]
  • [ 5326-47-6 ]
  • (S)-2-[2-(6-Iodo-4-oxo-2-phenyl-4H-quinazolin-3-yl)-acetylamino]-4-methyl-pentanoic acid [ No CAS ]
  • 25
  • [ 686-50-0 ]
  • [ 98-88-4 ]
  • [ 2789-92-6 ]
  • (S)-2-[2-(6,8-Dichloro-4-oxo-2-phenyl-4H-quinazolin-3-yl)-acetylamino]-4-methyl-pentanoic acid [ No CAS ]
  • 26
  • [ 686-50-0 ]
  • [ 98-88-4 ]
  • [ 609-85-8 ]
  • (S)-2-[2-(6,8-Dibromo-4-oxo-2-phenyl-4H-quinazolin-3-yl)-acetylamino]-4-methyl-pentanoic acid [ No CAS ]
  • 28
  • [ 686-50-0 ]
  • [ 82911-69-1 ]
  • [ 82007-05-4 ]
  • 29
  • [ 1187-50-4 ]
  • [ 61-90-5 ]
  • [ 686-50-0 ]
  • [ 141-43-5 ]
  • 43
  • l-leucyl-glycyl-l-alanine [ No CAS ]
  • [ 686-50-0 ]
  • 44
  • [ 686-50-0 ]
  • [ 110661-49-9 ]
  • sodium N-undecylenyl-L-leucyl-glycine [ No CAS ]
  • 45
  • [ 686-50-0 ]
  • [ 51908-29-3 ]
  • {(S)-4-Methyl-2-[3-(4-sulfamoyl-phenyl)-thioureido]-pentanoylamino}-acetic acid [ No CAS ]
  • 46
  • [ 26117-20-4 ]
  • [ 6000-44-8 ]
  • [ 686-50-0 ]
  • 47
  • [ 686-50-0 ]
  • <4S-(4α,12aα)>-9-(L-leucylglycylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide [ No CAS ]
  • 48
  • [ 686-50-0 ]
  • C46H50N4O9 [ No CAS ]
  • 49
  • [ 686-50-0 ]
  • ((S)-1-[((5R,5aR,6S,6aR,7S,10aS)-9-Carbamoyl-7-dimethylamino-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydro-naphthacen-2-ylcarbamoyl)-methyl]-carbamoyl}-3-methyl-butyl)-carbamic acid 9H-fluoren-9-ylmethyl ester [ No CAS ]
  • 52
  • [ 2867-06-3 ]
  • [ 686-50-0 ]
  • 53
  • [ 111411-33-7 ]
  • [ 686-50-0 ]
  • 54
  • [ 28659-88-3 ]
  • [ 686-50-0 ]
  • 55
  • [ 686-50-0 ]
  • L-leucine aminopeptidase [ No CAS ]
  • Cl-CH2-CO-Leu-Gly-O-C6H4-NO2(p) [ No CAS ]
  • 56
  • {Co(N-(2-picolyl)-1R,2R-diaminocyclohexane)Cl3} [ No CAS ]
  • [ 686-50-0 ]
  • sodium perchlorate [ No CAS ]
  • C-{Co(N-(2-picolyl)-1R,2R-diaminocyclohexane)(S-leucylglycinato)}ClO4*2.5H2O [ No CAS ]
  • 57
  • sodium tetrachloropalladate(II) [ No CAS ]
  • [ 686-50-0 ]
  • trans-Dichlorobis(L-leucinglycinato)palladium(II) [ No CAS ]
  • 58
  • cobalt(II) chloride hexahydrate [ No CAS ]
  • [ 686-50-0 ]
  • [ 4408-64-4 ]
  • barium(II) [ No CAS ]
  • Co(CH3N(CH2COO)2)2(1-) [ No CAS ]
  • Ba(2+)*2Co((CH3)N(CH2COO)2)(NH2CH(CH2CH(CH3)2)CONCH2(COO))(1-)*5H2O [ No CAS ]
  • Co(NH2CH(CH2CH(CH3)2)CONCH2(COO))2(1-) [ No CAS ]
  • 59
  • cobalt(II) chloride hexahydrate [ No CAS ]
  • [ 686-50-0 ]
  • K(1+)*[Co(NH2CH(CH2CH(CH3)2)C(O)NCH2COO)2](1-)*5.5H2O=K[Co(NH2CH(CH2CH(CH3)2)C(O)NCH2COO)2]*5.5H2O [ No CAS ]
  • K(1+)*[Co(NH2CH(CH2CH(CH3)2)C(O)NCH2COO)2](1-)*4H2O=K[Co(NH2CH(CH2CH(CH3)2)C(O)NCH2COO)2]*4H2O [ No CAS ]
  • 60
  • [ 686-50-0 ]
  • dipotassium [carbonato(bis-N,N-carboxymethyl-L-phenylalaninate)cobaltate(III)] [ No CAS ]
  • potassium chloride [ No CAS ]
  • potassium [(bis-N,N-carboxymethyl-L-phenylalaninate)(l-leucinate)cobaltate(III)] [ No CAS ]
  • potassium [(bis-N,N-carboxymethyl-L-phenylalaninate)(L-leucylglycinate)cobaltate(III)] [ No CAS ]
  • 61
  • (S)-2-hydroxy-2'-(3-(N-phenylcarbamoylamino)benzyl)-1,1'-binaphthyl-3-carboxaldehyde [ No CAS ]
  • [ 686-50-0 ]
  • C43H40N4O6 [ No CAS ]
  • 62
  • [ 51220-76-9 ]
  • [ 686-50-0 ]
  • [ 5815-67-8 ]
  • 63
  • [ 686-50-0 ]
  • [ 138-41-0 ]
  • Gly-Leu-CBS [ No CAS ]
  • 64
  • [ 686-50-0 ]
  • [ 1236032-77-1 ]
  • C8H16N2O3*C96H148N2O70S [ No CAS ]
  • 65
  • [ 850232-61-0 ]
  • [ 686-50-0 ]
  • [ 1385775-67-6 ]
  • 66
  • [ 686-50-0 ]
  • [ 1447757-89-2 ]
  • [ 1447757-94-9 ]
  • [ 1447757-99-4 ]
  • [ 63097-15-4 ]
  • 67
  • [ 686-50-0 ]
  • C26H42N6O6 [ No CAS ]
  • 68
  • [ 686-50-0 ]
  • C35H40N4O7 [ No CAS ]
  • 69
  • [ 686-50-0 ]
  • Fmoc-Gly-Phe-Leu-Gly-OH [ No CAS ]
  • 70
  • [ 686-50-0 ]
  • Fmoc-GFLG-ONp [ No CAS ]
  • 71
  • [ 686-50-0 ]
  • Fmoc-GFLG-ED-Boc [ No CAS ]
  • 72
  • [ 67-56-1 ]
  • [ 686-50-0 ]
  • [ 27560-15-2 ]
YieldReaction ConditionsOperation in experiment
With thionyl chloride; at 0℃;Reflux; H-GF-OH will be dissolved in methanol followed by the addition of pyridine. FmocOSu will be added to the reaction mixture and stirred overnight. The reaction mixture will be concentrated under vacuum followed by trituration with diethyl ether. This will be purified by column chromatography (silica gel) using ethyl acetate (EtOAc) and methanol as eluent. The fractions containing Fmoc-GF-OH will be concentrated and used in subsequent reaction without thrther purification. H-EG-OH will be dissolved in methanol and cooled to 0 C. followed by the addition of 50C12. The reaction mixture will be refluxed followed by the removal of solvent under vacuum. The product will be redissolved in toluene and concentrated under vacuum to remove traces of methanol and 50C12. The solid (EGOMe) will be dissolved in EtOAc and Fmoc-GF-OH will be added to it followed by the addition of DIPEA and HOP and stirred overnight. The solvent will be removed under vacuum and washed with H20 and extracted with EtOAc. The product will be purified by column chromatography (silica gel, eluent EtOAc:methanol; 9:1 v/v). The fraction containing Fmoc-GFEG-OMe will be concentrated under vacuum. Fmoc-GFEG-OMe will be dissolved in methanol and aqueous iN NaOH will be added dropwise at room temperature and stirred for 6 hours. The reaction mixture will be concentrated to 50% the volume and the pH of the solution will be adjusted to pH 3. The precipitate will be extracted with EtOAc. The EtOAc layer will be concentrated to give FmocGFEG-OH. The product will be identified by mass spectrometry. Fmoc-GFEG-OH will be dissolved in DMF (anhydrous) and cooled in an ice bath to -15 C., an excess of DCC solution will be added dropwise with constant stirring followed by an excess of p-nitrophenol (ONp) solution. The reaction mixture will be stirred for 3 hat-i 5C., followed by overnight at 4 C. and an additional 24 hat room temperature. Trace amounts of acetic acid (glacial) will be added to the solution to react with excess DCC. The precipitated byproduct DCU will be removed and the filtrate concentrated to obtain the product (Fmoc-GFEG-ONp). Recrystallization will be done from EtOH/H20 1:1 (v/v). Fmoc-GFEG-ONp will be dissolved in DCM followed by the addition of bocethylenediamine and TEA. The reaction mixture will be stirred and then concentrated followed by purification by colunm chromatography (silica gel, eluent EtOAc). The fractions containing Fmoc-GFEG-ED-Hoc was concentrated and analyzed by mass spectroscopy.
Same Skeleton Products
Historical Records